Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Management of dry eye in patients with ocular graft versus host disease

Poster Details

First Author: E. Erdem TURKEY

Co Author(s):    K. Gul   B. Karagun   M. Yagmur              

Abstract Details


To evaluate the treatment regimens for the management of patients with ocular graft versus host disease (OGVHD).


Cukurova University Faculty of Medicine, Adana/TURKEY


A retrospective case series of 10 patients with OGVHD was conducted. Complete history and ocular examination were performed. Clinical findings, complications and treatment regimens for both acute and chronic presentations of dry eye were evaluated.


Two female and 8 male patients [median age;22 years (8-52 years)] included to the study. Patients were followed mean 6 months (4-14 months). Six patients presented with acute exacerbation of dry eye, other 4 patients had chronic ocular discomfort. Topical loteprednol was prescribed as 8 times in a day in acute presented cases. N-acetyl-cysteine drop (4 times in a day) given in cases with filamentous keratitis. After that, topical cyclosporine A and non-preserved artificial drops were prescribed for maintaining treatment. Chronic dry eye symptoms were treated with topical cyclosporine A and non-preserved artificial drop. In steroid group; intraocular pressure increased in 2 cases, posterior subcapsular cataract was observed in 1 case.


Dry eye is the most common ocular presentation of OGVHD which may effect patients quality of life. Short term use of topical steroids seems very helpful for the management of acute symptoms. Ocular hypertension and cataract development should be keep in mind during follow-up. Non-preserved artificial tear drop with topical cyclosporine drop is a good option for long term control of chronic dry eye.

Financial Disclosure:


Back to Poster listing